Sirolimus Calmed Hepatosplenic Immune Dysregulation in a Complex CVID Case
Common variable immunodeficiency is usually framed as an antibody deficiency, but the disease often extends far beyond recurrent infection. In this 50-year-old patient, CVID had already been managed for five years with regular IVIG replacement when progressive hepatosplenomegaly and cytopenias emerged despite preventive care that appeared adequate on the infectious side. The clinical picture shifted toward immune dysregulation rather than simple susceptibility to microbes. Abdominal enlargement, dyspnea, fatigue, and heavy sweating became increasingly prominent, and the symptom burden grew hard to dismiss as menopausal change alone. Physical examination confirmed marked enlargement of both liver and spleen.
The bedside problem was urgent in a very specific way. Organomegaly in CVID can reflect benign-appearing immune activation, yet it can also sit uncomfortably close to malignant lymphoproliferation, and that overlap complicates management. Initial evaluation excluded acute infection and overt lymphoma, while abdominal imaging showed hepatosplenomegaly without focal lesions. Those findings made immune-mediated lymphoproliferation the most plausible working diagnosis. In that setting, the therapeutic question was not whether to intensify antibiotics or adjust immunoglobulin replacement. The question was whether a targeted immunomodulator could blunt the dysregulated T-cell and lymphoid activation driving organ expansion.
Why mTOR Inhibition Became the Therapeutic Pivot
Sirolimus entered the case as a steroid-sparing agent for presumed immune dysregulation. As an mTORC1 inhibitor, sirolimus has a biologically credible role in disorders defined by abnormal immune activation and lymphoproliferation. It is already familiar from transplant medicine, where suppression of proliferative immune signaling is part of its core utility. In CVID and related inborn errors of immunity, the same pathway can be relevant when hepatosplenomegaly and cytopenias suggest that immune cells are driving tissue enlargement more than infection is.
This patient’s course gives the mechanism clinical shape. During treatment, the spleen length fell from 23 cm before initiation to 13 cm after 5 months and 12 cm after 7 months. The liver size decreased from 18 cm to 15 cm over the same interval. Those are not trivial imaging changes; they indicate a substantial reduction in lymphoid and reticuloendothelial congestion at the organ level. The response supports the idea that at least part of the hepatosplenic burden in this case was biologically reversible once proliferative immune signaling was restrained.
Hematologic and Biochemical Response Tracked with the Organ Response
The platelet count improved from 37 to 75 × 10³/µL. That rise remained incomplete, but it matters because thrombocytopenia in this setting can reflect splenic sequestration, marrow stress, or broader immune-mediated cytopenia. A partial recovery in platelet count suggests the spleen was no longer acting as aggressively as a sink and that the inflammatory pressure on blood counts had eased. Liver enzymes moved in the same direction: aspartate aminotransferase declined from 77 to 58 U/L, and alanine aminotransferase dropped from 93 to 47 U/L. Alkaline phosphatase stayed elevated, so the biochemical improvement was incomplete rather than universal.
Two short conclusions emerge from that pattern. The first is that sirolimus produced a major organ response. The second is that hematologic recovery lagged behind the anatomic improvement.
Leukopenia and neutropenia persisted throughout treatment, which keeps the interpretation grounded. The drug did not normalize every abnormality, and it did not erase the underlying immune defect that defines CVID. Instead, it appears to have reduced the most visible manifestations of immune dysregulation while leaving residual marrow or peripheral cytopenic features behind. That mixed response is typical of immune-mediated disease control: the dominant phenotype may improve first, while downstream laboratory abnormalities resolve more slowly or incompletely.
Symptom Relief and Infectious Safety in a Patient Already Living with Immune Deficiency
Clinical benefit reached beyond the imaging suite. The patient reported improvement in constitutional symptoms and abdominal discomfort during sirolimus therapy, which aligned with the reduction in splenic and hepatic size. Dyspnea and fatigue had been part of the presenting syndrome, and less abdominal distension likely translated into better daily function. In a disease like CVID, symptom improvement is especially meaningful because organomegaly and systemic inflammation can erode quality of life even when overt infection is not the dominant issue.
No serious infectious complications occurred during treatment. That observation cannot be generalized too far from a single case, but it is still clinically important. Any immunosuppressive strategy in CVID must be judged against the risk of worsening infection susceptibility, particularly in a patient already dependent on IVIG replacement. The absence of major infectious toxicity in this course supports feasibility, not certainty. It suggests that sirolimus can be used without immediate infectious catastrophe in a carefully selected patient, but it does not establish a universal safety threshold.
What This Case Says About CVID-Associated Hepatosplenomegaly
CVID is the most common primary immunodeficiency in adults, yet its non-infectious complications often dictate the hardest clinical decisions. Hepatosplenomegaly, cytopenias, and constitutional symptoms force clinicians to consider immune dysregulation, lymphoproliferation, and lymphoma in the same diagnostic frame. This case demonstrates how a targeted pathway inhibitor can alter that trajectory when standard preventive care is no longer enough.
The value of the report lies in its combination of organ response, partial hematologic recovery, and symptom improvement. It also exposes the limits of current evidence. One patient cannot define who should receive mTOR inhibition, how long treatment should continue, or which laboratory and imaging features best predict benefit. The persistence of leukopenia, neutropenia, and elevated alkaline phosphatase also warns against overselling the effect as complete disease control.
Careful patient selection remains essential. In a CVID patient with progressive hepatosplenomegaly and cytopenias after infection and overt lymphoma have been excluded, sirolimus may deserve consideration when the clinical picture points toward immune-driven lymphoproliferation. The case supports that approach, but larger studies are still needed to define durability, safety, and the range of patients most likely to benefit from mTOR inhibition in CVID-associated immune dysregulation.